Immunome (NASDAQ:IMNM – Free Report) had its target price boosted by Wedbush from $12.00 to $19.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Immunome’s Q4 2023 earnings at ($0.37) EPS, FY2023 earnings at ($1.16) EPS, FY2024 earnings […]
Immunome (NASDAQ:IMNM – Free Report) had its target price hoisted by Wedbush from $12.00 to $19.00 in a research note released on Tuesday, Benzinga reports. The brokerage currently has an outperform rating on the stock. Wedbush also issued estimates for Immunome’s Q4 2023 earnings at ($0.37) EPS, FY2023 earnings at ($1.16) EPS, FY2024 earnings at […]
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) hit a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $12.00 to $19.00. Wedbush currently has an outperform rating on the stock. Immunome traded as high as $16.02 and last traded at $15.08, with a volume of 144702 shares. […]
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares reached a new 52-week high on Tuesday after Wedbush raised their price target on the stock from $12.00 to $19.00. Wedbush currently has an outperform rating on the stock. Immunome traded as high as $16.02 and last traded at $15.08, with a volume of 144702 shares. The […]
By Chris Wack Immunome and Zentalis Pharmaceuticals entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis.